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ABSTRACT
Widespread reliance on animal models during preclinical research and toxicity testing assumes their reasonable
predictivity for human outcomes. However, of 20 published systematic reviews examining human clinical utility
located during a comprehensive literature search, animal models demonstrated significant potential to contribute
toward clinical interventions in only two cases, one of which was contentious. Included were experiments expected by
ethics committees to lead to medical advances, highly-cited experiments published in major journals, and
chimpanzee experiments—the species most generally predictive of human outcomes. Seven additional reviews failed
to demonstrate utility in reliably predicting human toxicological outcomes such as carcinogenicity and teratogenicity.
Results in animal models were frequently equivocal, or inconsistent with human outcomes. Consequently, animal
data may not be considered generally useful for these purposes. Regulatory acceptance of non-animal models is
normally conditional on formal scientific validation. In contrast, animal models are simply assumed to be predictive of
human outcomes. These results demonstrate the invalidity of such assumptions. The poor human clinical and
toxicological utility of animal models, combined with their generally substantial animal welfare and economic costs,
demand greater rigor within animal studies, and justify a ban on animal models lacking scientific data clearly
establishing their human predictivity or utility.

LABORATORY ANIMAL USE: A MEDICAL CONTROVERSY
Annually, many millions of animals are used worldwide in toxicity testing and biomedical research aimed
at developing cures for human diseases. Steady increases in the use of genetically modified animals and
several large-scale chemical testing programs within the US and Europe are increasing laboratory animal
use [1].
Yet biomedical research using laboratory animals remains highly controversial. Advocates frequently
claim such research is vital for preventing, curing or alleviating human diseases [e.g., 2-3], that the
greatest achievements of medicine have been possible only due to the use of animals [e.g., 4], and that
the complexity of humans requires nothing less than the complexity of laboratory animals, to effectively
model, during biomedical investigations [5]. They even claim that medical progress would be “severely
maimed by prohibition or severe curtailing of animal experiments,” and that “catastrophic consequences
would ensue” [6].
However, such claims are hotly contested [e.g., 7], and a growing body of empirical evidence casts doubt
upon their scientific utility as experimental models of humans [e.g., 8-10]. The right of humans to
experiment on animals has also been strongly contested philosophically [e.g., 11-12].

SYSTEMATIC REVIEWS OF CLINICAL UTILITY
Numerous cases of discordance between human and laboratory animal outcomes, [e.g., 13], cast doubt
on the human predictivity and reliability of animal models, despite their widespread use in human toxicity
testing, and in the safety and efficacy testing of putative chemotherapeutic agents and other clinical
interventions.
However, only small numbers of experiments are normally reviewed in such case studies, and their
selection may be subject to bias. To provide more definitive conclusions, systematic reviews of the human
clinical or toxicological utility of large numbers of animal experiments are necessary. Experiments
included in such reviews are selected without bias, via randomization or similarly methodical and impartial
means.
In recent years a growing number of such reviews and meta-analyses have been published, which
collectively provide important insights into the human clinical and toxicological utility of animal models. To
locate and analyze them, in 2007 I searched the Scopus Life and Health Sciences biomedical
bibliographic databases for systematic reviews of the human clinical or toxicological utility of animal
experiments that had been successfully published in the peer-reviewed biomedical literature. Among the
world’s most comprehensive, the Life Sciences database includes over 3,400 titles, and the Health
Sciences database includes over 5,300 titles [14], including all of Medline, the leading medical and allied
health profession database, which itself contains over 15 million citations, sourced from more than 5,000
biomedical journals from over 80 countries [15].
All abstracts, titles and key words were searched for (animal experiment OR animal model OR animal
study OR animal trial) AND (clinical trial OR human outcome OR human relevance OR human result).
Results were limited to articles or reviews, and no other limitations were applied. Additional relevant
studies were obtained by examination of reference lists of retrieved papers, and by consultation with
colleagues working in this field.
To minimize bias, reviews were selected only when systematically conducted using randomization or
similarly methodical and impartial means to select animal studies. For example, in some cases all animal
studies within relevant subsets of toxic chemical databases were examined, without exclusion.
Only reviews examining the contributions of animal experiments toward the development of prophylactic,
diagnostic or therapeutic interventions with clear potential for combating human diseases or injuries, or
their consistency with human clinical outcomes, or their human toxicological predictivity or utility, were
examined. Reviews focusing only on the contributions of animal experiments towards increased
understanding of a wide range of other biomedical concepts, including the etiological, pathogenesic or
other aspects of human diseases, or on the clinical utility of animal experiments in non-human species,
for example, were not included.
As of 1st March 2007, 20 systematic reviews examining the contributions of animal experiments toward
the development of human clinical interventions, and seven reviews examining their utility during the
assessment of human toxicity, were located [1]. Of the 20 clinical reviews, authors concluded that animal
models had the potential to be significantly useful in contributing to the development of clinical
interventions in only two cases, one of which was contentious. Results in animal models were frequently
equivocal, or inconsistent with human clinical outcomes. Of the seven toxicological reviews, none clearly
demonstrated the utility of animal models in reliably predicting human toxicological outcomes, such as
carcinogenicity and teratogenicity. Three different approaches that sought to determine the maximum
human clinical utility that may be achieved by animal experiments were of particular interest.

Animal Experiments Expected to Lead to Medical Advances
Lindl and colleagues [16-17] examined animal experiments conducted at three German universities
between 1991 and 1993 that had been approved by animal ethics committees at least partly on the basis
of claims by researchers that the experiments might lead to concrete advances toward the cure of human
diseases. Experiments were included only where previous studies had shown that the applications of
related animal research had confirmed the hypotheses of the researchers, and where the experiments
had achieved publication in biomedical journals.
For 17 experiments meeting these inclusion criteria, citations were analyzed for at least 12 years. Citation
frequencies and types of citing papers were recorded: whether reviews, or animal-based, in vitro or
clinical studies. 1,183 citations were evident; however, only 8.2% of all citations (97) were in clinical
publications, and of these, only 0.3% of all citations (four publications) demonstrated a direct correlation
between the results of animal experiments and human outcomes. However, even in these four cases the
hypotheses that had been verified successfully in the animal experiment failed in every respect when
applied to humans. None of these 17 experiments led to any new therapies, or had any beneficial clinical
impact during the period examined.
Accordingly, Lindl and colleagues called for serious, rather than cursory, evaluations of the likely benefits
of animal experiments by animal ethics committees and related authorities, and for a reversal of the
current paradigm in which experiments are routinely approved. Instead of approving experiments
because of the possibility that benefits may accrue, Lindl and colleagues asserted that where significant
doubt exists, laboratory animals should receive the benefit of that doubt, and such experiments should
not, in fact, be approved.
Highly-Cited Animal Experiments
Hackam and Redelmeier [18] also utilized a citation analysis. Based on the premise that findings from
highly-cited animal experiments would be most likely to be subsequently tested in clinical trials, they
searched for experiments with more than 500 citations published in the seven leading scientific journals
when ranked by citation impact factor.
Of 76 animal studies located with a median citation count of 889 (range: 639-2,233), only 36.8% (28/76)
were replicated in randomized human trials. 18.4% (14/76) were contradicted by randomized trials, and
44.7% (34/76) had not translated to clinical trials. Ultimately, only 10.5% (8/76) of these medical
interventions were subsequently approved for use in patients.
Even in these cases human benefit cannot be assumed, because adverse reactions to approved
interventions are sufficiently common that they were recently recorded as the 4-6th leading cause of
death in US hospitals [based on a 95% confidence interval; 19], a rate considered by these investigators
to be “extremely high.” Such limited predictivity for wider human outcomes of human clinical trials may
result from their focus on small groups of healthy young men, and from insufficient study durations.
Particularly in Phase III, small cohorts of young men (20-300) are typically used to minimize experimental
variability and to eliminate possible endocrinological disruption or other risks to women of reproductive
age. Although 1,000-3,000 volunteers may be used in Phase III trials— the final phase before marketing
[20], it is nevertheless clear that cohort numbers, study durations or other aspects of protocol design,
conduct or interpretation are inadequate to detect the adverse side effects of the considerable number of
pharmaceuticals that harm patients after marketing. Longer studies of more broadly representative
human populations would be more predictive, but would increase the time and cost of pharmaceutical
development, and are resisted by pharmaceutical companies.

The low rate of translation to clinical trials of even these highly-cited animal experiments occurred despite
1992 being the median publication year, allowing a median of 14 years for potential translation. For
studies that did translate to clinical trials, the median time for translation was seven years (range one to
15). Frequency of translation was unaffected by laboratory animal species, type of disease or therapy
under examination, journal, year of publication, methodological quality, and even, surprisingly, citation
rate. However, animal studies incorporating dose-response gradients were more likely to be translated to
clinical trials (odds ratio [OR] = 3.3; 95% confidence interval [CI] = 1.1 - 10.1).
Although the rate of translation of these animal studies to clinical trials was low, as Hackam and
Redelmeier stated, it is nevertheless higher than that of most published animal experiments, which are
considerably less likely to be translated than these highly-cited animal studies published in leading
journals. Furthermore, the selective focusing on positive animal data while ignoring negative results
(optimism bias), is one of several cited factors that may increase the likelihood of translation beyond that
scientifically merited. As Hackam [21] stated, rigorous meta-analysis of all relevant animal experimental
data would probably significantly decrease the translation rate to clinical trials.
Additionally, only 48.7% (37/76) of these highly-cited animal studies were of good methodological quality.
Despite their publication in leading scientific journals, few included random allocation of animals to
treatment groups, adjustment for multiple hypothesis testing, or blinded assessment of outcomes.
Accordingly, Hackam and Redelmeier cautioned patients and physicians about extrapolating the findings
of even highly-cited animal research to the care of human disease.
Chimpanzee Experiments
Chimpanzees are the species most closely related to humans, and consequently, most likely to be
predictive of human outcomes when used in biomedical research. Accordingly, in 2005 I conducted a
citation analysis examining the human clinical utility of chimpanzee experimentation [22].
I searched three major biomedical bibliographic databases, locating 749 papers published between 1995
and 2004 that described experiments on captive chimpanzees or their tissues. Although published in the
international scientific literature, the vast majority of these experiments were conducted within the US
[23].
Within a statistically-significant subset of 95 randomly-selected published chimpanzee experiments,
49.5% (47/95) were not cited by any subsequent papers, demonstrating minimal contribution toward the
advancement of biomedical knowledge generally. This is of particular concern, because research of
lesser value is not published; hence these results indicate that the majority of chimpanzee research
generates data of questionable value, which makes little obvious contribution towards the advancement
of biomedical knowledge.
35.8% (34/95) of 95 published chimpanzee experiments were cited by 116 papers that clearly did not
describe well-developed methods for combating human diseases. Only 14.7% (14/95) were cited by 27
papers that abstracts indicated described well-developed methods for combating human diseases.
However, detailed examination of these medical papers revealed that in vitro studies, human clinical and
epidemiological studies, molecular assays and methods, and genomic studies, contributed most to their
development. 63.0% (17/27) were wide-ranging reviews of 26-300 (median 104) references, to which the
cited chimpanzee study made a very small contribution. Duplication of human outcomes, inconsistency
with other human or primate data, and several other causes, resulted in the absence of any chimpanzee
study able to demonstrate an essential contribution, or, in most cases, a significant contribution of any
kind, toward the development of the medical method described.

Despite the low utility of chimpanzee experiments in advancing human health indicated by these results, it
remains true that chimpanzees are the species most closely related to human beings. Hence, it is highly
likely that other laboratory species are even less efficacious when used as experimental models of
humans in biomedical research and toxicity testing.
Animal Models of Stroke and Head Injuries
Despite the existence of experimental literature describing the efficacy of more than 700 drugs in treating
experimental models of stroke (artificially-induced focal cerebral ischemias) [24], only recombinant tissue
plasminogen activator (rt-PA) and aspirin have convincingly demonstrated efficacy in human clinical trials
of acute ischaemic stroke [25-27]. Macleod and colleagues [24] stated that, “This failure of putative
neuroprotective drugs in clinical trials represents a major challenge to the doctrine that animals provide a
scientifically valid model for human stroke.” At least 10 published systematic reviews have described the
poor human clinical utility of animal experimental models of stroke [24, 28-36].
In some cases clinical trials proceeded despite equivocal evidence of efficacy in animal studies. Horn and
colleagues [29], for example, systematically reviewed 20 animal studies of the efficacy of nimodipine, of
which only 50% showed beneficial effects following treatment. They concluded that, “... the results of this
review did not show convincing evidence to substantiate the decision to perform trials with nimodipine in
large numbers of patients.” These human clinical trials also demonstrated equivocal evidence of efficacy,
and furthermore, proceeded concurrently with the animal studies, despite the fact that the latter should be
conducted prior to clinical trials, to allow detection of potential toxicity.
O’Collins and colleagues [30] conducted a very large review of 1,026 experimental treatments for acute
stroke, finding that the effectiveness in animals of 114 drugs chosen for human clinical use was no
greater than that of the remaining 912 drugs not chosen for clinical use, thereby demonstrating that
effectiveness in animal models had no measurable effect on whether or not these drugs were selected for
human clinical use. Accordingly, O’Collins and colleagues questioned whether the most efficacious drugs
are, in fact, being selected for clinical trials, and called for greater rigor in the conduct, reporting, and
analysis of animal experiments.
In many cases animal models did indicate efficacy, but these successes did not translate to humans. In a
few cases authors speculated about the possible causes. Jonas and colleagues [31], for example,
hypothesized that poor clinical efficacy of neuroprotectants successful in animal models was due to
differences in the timing of treatment initiation. Curry [32] hypothesized that the clinical failure of fourteen
neuroprotective agents successful in animal models was due to antagonism of glutamate—which may be
associated with neuroprotection—by drug treatment in clinically normal patients, and that that clinical
trials should be restricted to real patients, who experience elevated cerebrospinal fluid and plasma
glutamate levels during progressing stroke. However, despite such speculation, the human clinical record
of neuroprotectants successful in animal models remains poor.
The utility of the majority of these animal studies also appears to have been impeded by their poor
methodological quality (20 animal studies of the efficacy of nimodipine [29]; animal studies of the efficacy
of melatonin [24]; 29 animal studies of the efficacy of FK506 [28]; 45 animal studies of five compounds
from different classes of alleged neuroprotective agents—clomethiazole, gavestinel, lubeluzole, selfotel,
and tirilazad mesylate [33]; 25 animal studies of the efficacy of nitric oxide (NO) donors and L-arginine
[34]; 73 animal studies of the efficacy of NO synthase inhibitors [35]).
Methodological quality of animal studies was typically scored based on the presence of characteristics
such as appropriate animal models (aged, diabetic or hypertensive animals are considered to more

closely model human stroke patients), power calculations of sample sizes, random allocation to treatment
and control groups, use of a clinically relevant time window for commencement of treatment, blinded drug
administration, use of anesthetics without significant intrinsic neuroprotective activity (ketamine, for
example, may alter neuroprotective activity), blinded induction of ischemia (given that the severity of
induced infarcts may be subtly affected by knowledge of treatment allocation), blinded outcome
assessment, assessment of both infarct volume and functional outcome, adequate monitoring of
physiological parameters, assessment during both the acute (e.g., one to six days) and chronic (e.g.,
seven to 30 days) phases, statement of temperature control, compliance with animal welfare regulations,
peer reviewed publication, and conflict of interest statements. Typically, one point was given for the
presence of each characteristic. The Stroke Therapy Academic Industry Roundtable recommendations
for standards regarding preclinical and restorative drug development use an eight point scale, for
example [29, 37].
Median quality scores were four out of 10 (range zero to six, 13 studies [24]), four out of 10 (range zero to
seven, 29 studies [28]), three out of 10 (45 studies [33]), three out of eight (range one to six, 73 studies
[35]).
Common deficiencies included lack of: sample size calculations, aged animals or those with appropriate
co-morbidities, randomized treatment allocation, blinded drug administration, blinded induction of
ischemia, blinded outcome assessment and conflict of interest statements. Some studies also used
ketamine anesthesia, and there was also substantial variation in the parameters assessed.
van der Worp and colleagues [33], for example, concluded that the collective evidence for neuroprotective
efficacy that formed the basis for 21 clinical trials was obtained in animal studies of a methodological
quality that would not, in retrospect, justify such a decision.
Wilmot and colleagues [34] also found considerable variations in animal experimental protocols, namely:
animal species, physiological parameters such as blood pressure, drug administration (timing, dosage,
and route), surgical methodology, and duration of ischemia. Statistical analysis (Egger’s test) also
revealed the likely existence of publication bias (an increased tendency to publish studies in which a
treatment effect is apparent, or a decreased tendency to so publish, e.g., resulting from commercial
pressures, particularly in the case of patented drugs under development).
Macleod and colleagues [24] commented that, “these deficiencies apply to most if not all of the animal
literature.” This is particularly concerning, because Macleod and colleagues [28] reported that efficacy
was apparently lower in higher quality studies, raising concerns that apparent efficacy may have been
artificially elevated by factors such as poor methodological quality and publication bias.
A related review not limited solely to stroke exemplified some of these points. Perel and colleagues [36]
examined therapeutic interventions with unambiguous evidence of a treatment effect (benefit or harm) in
clinical trials of corticosteroidal treatment for head injury, antifibrinolytics in hemorrhage, thrombolysis in
acute ischemic stroke, tirilazad in acute ischemic stroke, antenatal corticosteroids to prevent neonatal
respiratory distress syndrome, and bisphosphonates to treat osteoporosis. They found that three
interventions had similar outcomes in animal models, while three did not, suggesting that animals do not
reliably predict human outcomes. Perel and colleagues reported that the animal studies varied in
methodological quality and sample sizes, that randomization and blinding were rarely reported, and that
publication bias was evident.

Animal Models in Other Clinical Fields
Of seven systematic reviews examining the utility of animal models in other clinical fields identified by this
review [38, 39 and 40 (which jointly described a single review), 41-45], authors concluded that animal
models had the potential to contribute significantly toward human clinical interventions in only two cases,
one of which was contentious.
As in the case of stroke, some clinical trials proceeded despite equivocal evidence of efficacy in animal
studies. Upon systematically reviewing the effects of Low Level Laser Therapy (LLLT) on wound healing
in 36 cell or animal studies, Lucas and colleagues [38] found that in-depth analysis of studies with the
highest methodological quality showed no significant pooled treatment effect. Despite this, clinical trials
proceeded. Furthermore, almost from the beginning of LLLT investigations, animal experiments and
clinical studies occurred simultaneously, rather than in sequence. The human trials also failed to
demonstrate significant benefits.
Roberts and colleagues [39], and Mapstone and colleagues [40], all systematically reviewed 44
randomized controlled animal studies examining the efficacy of fluid resuscitation in bleeding animals.
Their systematic review of clinical trials of fluid resuscitation had previously found no evidence that the
practice improved outcomes, and the possibility that it might be harmful [46]. In this later review [39-40],
they found that fluid resuscitation reduced mortality in animal models of severe hemorrhage, but
increased mortality in those with less severe hemorrhage.
After clinical trials in humans failed to provide evidence of benefit, Lee and colleagues [41] conducted a
systematic review and meta-analysis of controlled trials of endothelin receptor blockade in animal models
of heart failure. Meta-analysis failed to provide evidence of overall benefit, and indicated increased
mortality with early administration.
In their investigation of the contribution of human clinical trial results and analogous experimental studies
to asthma research—one of the most common and heavily investigated of modern diseases, Corry and
Kheradmand [42] demonstrated that failure to conduct and analyze the results of animal studies before
proceeding to clinical trials is not uncommon: “Research along two fronts, involving experimental models
of asthma and human clinical trials, proceeds in parallel, often with investigators unaware of their
counterpart's findings.”
The clinical utility of animal models is clearly questionable in such cases in which clinical trials proceed
concurrently with, or prior to, animal studies, or continue, despite equivocal evidence of efficacy in
animals.
As in the case of stroke, the clinical utility of the majority of these animal studies also appears to have
been limited by their poor methodological quality (36 cell or animal studies of the effect of LLLT on wound
healing [38]; 44 studies examining the efficacy of fluid resuscitation in bleeding animals [39-40]; studies of
the efficacy of endothelin receptor blockade in animal models of heart failure [41]). Common flaws
included inadequate sample sizes, leaving studies underpowered, and lack of randomization and blinding.
In some cases obvious deficiencies with the animal models were identified. In commenting on the clinical
relevance of animal models for testing the effects of LLLT on wound healing, Lucas et al. [38] noted that
the animal models excluded common problems associated with wound healing in humans, such as
ischemia, infection, and necrotic debris.
Difficulty was also apparent in translating animal outcomes to human clinical protocols in at least one
case. Lazzarini and colleagues [43] reviewed experimental studies on osteomyelitis to ascertain their

impacts on the systemic antibiotic treatment of human osteomyelitis. Although they found that most of the
animal models reviewed were reproducible and dependable, they also found that the human predictivity
of these studies was unclear, and was possibly undermined by difficulties in establishing the right dose
regimen in animals. Although they considered that the use of antibiotic combinations was associated with
better outcomes in the majority of animal studies, and that these studies did provide indications of
appropriate minimum treatment durations, they concluded that these studies had limited impact on clinical
practice.
In two cases reviewers reported consistency between animal models and human outcomes that appeared
to offer potential in contributing to the development of clinical interventions, although in one case this
conclusion was contentious. While reviewing therapeutic approaches to streptococcal endocarditis,
Scheld [44] reported good correlation overall among results obtained by in vitro susceptibility testing
(especially killing kinetics in broth), experimental animal results, and clinical trials of different antimicrobial
regimens in humans with streptococcal endocarditis.
To investigate the efficacy of rodent models of carcinogenesis in predicting treatment outcomes in
humans, Corpet and Pierre [45] conducted a systematic review and meta-analysis of colon cancer
chemoprevention studies using aspirin, -carotene, calcium, and wheat bran in rats, mice and humans.
Controlled intervention studies of adenoma recurrence in human volunteers were compared with
chemoprevention studies of carcinogen-induced tumors in rats, and of polyps in Min (Apc(+/-)) mice.
6,714 humans, 3,911 rats and 458 mice were included in the meta-analyses. Corpet and Pierre found that
rats and humans experienced comparable results using aspirin, calcium, carotene and wheat bran. Min
mice and humans results experienced comparable results using aspirin, but discordant results using
calcium and wheat bran (comparative carotene results were not available). Corpet and Pierre concluded
that these results suggested that rodent models roughly predict treatment effects in humans, but that the
prediction is not accurate for all agents, and that the carcinogen-induced rat model is more predictive than
the Min mouse model. However, few agents were tested, and two of three agents tested in mice
produced different outcomes in humans, so the conclusion that rodents are predictive of human treatment
effects, although only roughly, was contentious.
Toxicological Utility of Animal Experiments
Due to limited human exposure data, the identification and regulation of exposure to potential human
toxins has traditionally relied heavily on animal studies. However, systematic reviews have indicated that
the utility of animal studies for these purposes is lacking in the fields of carcinogenicity testing (at least
five reviews: [47-51]), and teratology testing (one review: [52]). No systematic review demonstrated a
contrary result. The sensitivity of animal models to a range of human toxicities (ability to identify them)
highlighted by one review [53] generally appears to be accompanied by poor human specificity (ability to
correctly identify human non-toxins), resulting in a high incidence of false-positive results.

ANIMAL EXPERIMENTAL CHARACTERISTICS LIMITING HUMAN UTILITY
When evaluated overall, these 27 systematic reviews clearly do not support the widely held assumptions
of animal ethics committees and the opinions of advocates that animal experiments are generally
beneficial in the development of human therapeutic interventions, and the assessment of human toxicity.
On the contrary, they frequently demonstrate that animal experiments are of low utility for these purposes.
This results both from limitations of the animal models themselves, and also from the poor methodological
quality and statistical design of many animal experiments.

Genetic Differences Between Human and Animals
Chimpanzees are our closest living relatives, and consequently might be expected to have the greatest
likelihood among laboratory species of accurately predicting human outcomes during preclinical research.
However, despite great similarity between the structural regions of chimpanzee and human DNA,
important differences between the regulatory regions exert an “avalanche” effect upon large numbers of
structural genes [54]. Despite nucleotide difference between chimpanzees and humans of only 1-2%, the
results are differences of around 20% in protein expression [55], resulting in marked phenotypic
differences between the species. These differences manifest in altered susceptibility to, etiology and
progression of diseases; differing absorption, tissue distribution, metabolism, and excretion of
chemotherapeutic agents; and differences in the toxicity and efficacy of pharmaceuticals [22, 54]. Such
effects appear to be responsible for the demonstrated inability of most chimpanzee research to contribute
substantially to the development of methods efficacious in combating human diseases [22].
Other laboratory animal species are even less similar to humans, both genetically and phenotypically, and
are therefore less likely to accurately model the progression of human diseases, or human responses to
putative chemotherapeutic agents or toxins.
Toxicity Testing
Rodents are by far the most common laboratory animal species used in toxicity studies. Several factors
contribute to the demonstrated inability of rodent bioassays to reliably predict human toxicity. The
stresses incurred during handling, restraint, other routine laboratory procedures, and particularly, the
stressful routes of dose administration common to toxicity tests, alter immune status and disease
predisposition in ways which are very difficult to accurately predict, distorting disease progression and
responses to putative toxic and chemotherapeutic agents [56-57].
Additionally, animals have a broad range of physiological defenses against general toxic insults, such as
epithelial shedding and inducible enzymes, which commonly prove effective at environmentally relevant
doses, but which may be overwhelmed at the high doses common to toxicity assays [58]. Carcinogenicity
assays also utilize chronic dosing. These may result in insufficient rest intervals between doses for the
effective operation of DNA and tissue repair mechanisms, which, as with the unnatural elevation of cell
division rates during ad libitum feeding studies, may predispose to mutagenesis and carcinogenesis.
Lower doses, greater intervals between exposures, intermittent feeding, or shorter total periods of
exposure, which represent a more realistic model of human environmental exposures to most potential
toxins, might not result in toxic changes at all [57].
Finally, differences in rates of absorption and transport mechanisms between test routes of administration
and other important human routes of exposure, and the considerable variability of organ systems in
response to toxic insults, between and within species, strains and genders, render profoundly difficult any
attempt to accurately extrapolate human hazards from animal toxicity data [57].
Methodological Quality
At least 11 systematic reviews [18, 24, 28-29, 33-36, 38, 39 and 40 (which described a single review), 41]
demonstrated the poor methodological quality of many of the animal experiments examined, and no
systematic review demonstrated good methodological quality of a majority of experiments. While omission
of study details due to publication space constraints may artificially lower apparent quality [24-28], the
prevalence of such deficiencies exceeds that which might reasonably be expected, and is therefore
grounds for considerable concern.

Common deficiencies included, lack of: sample size calculations, sufficient sample sizes, appropriate
animal models (particularly, aged animals or those with appropriate co-morbidities, as stroke models),
randomized treatment allocation, blinded drug administration, blinded induction of ischemia in the case of
stroke models, blinded outcome assessment, and conflict of interest statements. Some studies also used
anesthetics that may have altered experimental outcomes, and substantial variation was evident in the
parameters assessed.
These deficiencies limited the clinical utility of these studies in various significant ways. For example, it is
well established that studies that lack randomization or blinding often over-estimate the magnitude of
treatment effects [59-61]. Bebarta and colleagues [62] described the impacts of lack of randomization or
blinding on estimations of the significance of treatment effects in 389 animal studies and 2,203 cell line
studies. They found that studies lacking randomization or blinding but not both were more likely to report
a treatment response than studies that utilized these measures (OR = 3.4, 95% CI = 1.7 - 6.9; and OR =
3.2, 95% CI = 1.3 - 7.7, respectively), and that studies lacking both randomization and blinding were even
more likely to report a treatment response (OR = 5.2, 95% CI = 2.0 - 13.5).
Statistical Design
Insufficient sample sizes left many studies underpowered, limiting the statistical validity of study
conclusions. Animal lives and other resources may also be wasted, if experiments subsequently require
repetition. As stated by the UK Medical Research Council [63], “The number of animals used … must be
the minimum sufficient to create adequate statistical power to answer the question posed.”
According to Balls and colleagues [64], however, “…surveys of published papers as well as more
anecdotal information suggest that more than half of the published papers in biomedical research have
statistical mistakes, many seem to use excessive numbers of animals, and a proportion are poorly
designed”.
Festing [65] similarly stated that, “Surveys of published papers show that there are many errors both in
the design of the experiments and in the statistical analysis of the resulting data. This must result in a
waste of animals and scientific resources, and it is surely unethical.” de Boo and Hendriksen [66] noted
the tendency to alter animal numbers based on scientifically irrelevant issues such as availability or cost.
Factors that should be considered when calculating appropriate sample sizes include detectability
threshold (the size of the difference between treatment groups considered significant); known or expected
data variation; the required significance of the test (‘p’ or ‘α’; the probability of a Type I error—assuming a
difference where none exists); the acceptable probability of assuming no difference where one does exist
(‘β’; a Type II error. The ‘power’ of an experiment = 1-β; 0.8 is the usual choice); and the type of statistical
analysis to which the data will be subjected. Smaller thresholds, greater data variation, smaller
acceptable error probabilities (greater power) and certain statistical tests for differences require larger
samples.
No universal rule for calculating correct sample sizes exists [66]. Festing [67], for example, describes two
methods, the preferred ‘power calculation,’ and the ‘resource equation.’ Power calculations utilizing
formulae are available within interactive computer programs (e.g., [68-69]), and calculate minimum
sample sizes required to detect treatment effects with specified degrees of certainty. Mead’s ‘resource
equation’ [70] calculates sample sizes using degrees of freedom, and incorporates statistical parameters
such as treatment effects, block effects and error degrees of freedom.
Strategies should also be considered to minimize animal numbers without unacceptably compromising
statistical power. Several of these aim to decrease data variability by minimizing heterogeneity in

experimental environments and protocols; by the appropriate use of environmental enrichment to
decrease physiological variation, by choosing, where possible, to measure variables with relatively low
inherent variability, by the use of genetically homogeneous (isogenic or inbred) or specified pathogen free
animal strains, and by screening raw data for obvious errors or outliers [66, 71-73].
Meta-analysis involves the aggregation and statistical analysis of suitable data from multiple experiments.
Treatment and control groups may be combined, allowing group numbers to be minimized. Although new
information can be derived through meta-analysis, more frequently the results allow refinement of existing
knowledge. By designing experiments and reporting protocols to maximize their utility for later metaanalyses, the benefit of individual randomized controlled experiments may be maximized [74].
Strategies such as these, aimed at maximizing the statistical power of small samples, are particularly
appropriate when marked ethical, cost or practical constraints limit the number of animals that may be
used, e.g., during primate experiments.
Finally, appropriate statistical analysis of resultant data should be closely linked to experimental design
and to the type of data produced [75].
The relatively poor statistical knowledge of many animal researchers may be the cause of the high
prevalence of poor sample size choices in animal studies. Solutions could include statistical training of
researchers, and direct input of statisticians in experimental design and data analysis [66, 76].
IMPROVING EXPERIMENTAL STANDARDS
Evidence-based medicine (EBM) bases clinical decisions on methodologically-sound, prospective,
randomized, blinded, controlled clinical trials, and the gold standard for EBM is large prospective
epidemiological studies, or meta-analyses of randomized, blinded, controlled clinical trials [77]. The
implementation to animal experiments of EBM standards applied to human clinical trials would make
results more robust and broadly applicable [36, 78-81].
Mechanisms would be needed to ensure compliance with such standards, however. Compliance could,
for example, be made prerequisite for research funding, ethics committee approval, and publication of
results. These measures would require the education and cooperation of funding agencies, ethics
committees and journals.
The UK Medical Research Council requires researchers who are planning clinical trials to reference
systematic reviews of previous related work before proceeding [82]. To facilitate the detection of toxicity
and potentially efficacious drugs, such reviews should also include all relevant animal research [36]. A
similar requirement to reference, or where necessary, conduct, systematic reviews of relevant animal
studies prior to commencing further animal studies, would encourage a more complete and impartial
assessment of existing evidence [82].
Mechanisms are also needed to encourage the reporting of negative results. Negative preclinical studies
are much more likely to remain unpublished than negative clinical trials [83]. In a systematic review of
studies describing the efficacy of nicotinamide in combating experimentally-induced stroke, comparisons
published only in abstract form gave a significantly lower estimate of effect size than those published in
full, demonstrating publication bias [84]. Commenting on the pressure to obtain and publish positive
results, van der Worp and colleagues [33] stated: “It is therefore conceivable that the career of a
preclinical investigator is more dependent on obtaining positive results than that of a clinical trialist.”

Theoretical and Technical Constraints of Animal Models
Strategies designed to increase full and impartial examination of existing data before conducting animal
studies, to decrease variation in experimental environments and protocols, and to improve their
methodological quality, would minimize consumption of animal, financial and other resources within
experiments of questionable merit and quality, and would increase the potential human utility of animal
data. However, while these problems might be minimized with concerted effort, given their widespread
nature, the poor human clinical or toxicological utility of most animal experiments is unlikely to result
solely from such factors alone. As stated by Perel and colleagues [36], the failure of animal models to
adequately represent human disease may be another fundamental cause, which, in contrast, is likely to
be technically and theoretically impossible to overcome.
Genetic modification of animal models through the addition of foreign genes (transgenic animals), or
inactivation or deletion of genes (knockout animals), is being attempted, to make them more closely
model humans. However, as well as being technically difficult very to achieve, such modification may not
allow clear conclusions, due to a large variety of factors, including those reflecting the intrinsic complexity
of living organisms, such as the variable redundancy of some metabolic pathways between species [85].
Furthermore, the animal welfare burdens incurred during the creation and utilization of genetically
modified animals are particularly high [86].
CONCLUSIONS
The historical and contemporary paradigm that animal models are generally reasonably predictive of
human outcomes provides the basis for their widespread use in toxicity testing, and in biomedical
research aimed at developing cures for human diseases. However, their use persists for historical and
cultural reasons, rather than because they have been demonstrated to be scientifically valid. For
example, many regulatory officials “feel more comfortable” with animal data [87], and some even believe
animal tests are inherently valid, simply because they are conducted in animals [88].
However, most published systematic reviews have demonstrated that animal experiments are
insufficiently predictive of human outcomes to provide substantial benefits during the development of
human clinical interventions, or during human toxicity assessments. Of 20 reviews examining clinical
utility, animal models offered potential to be of significant use during the development of clinical
interventions in only two cases, one of which was contentious. Seven additional reviews failed to
demonstrate utility in reliably predicting human toxicological outcomes such as carcinogenicity and
teratogenicity. Results in animal models were frequently equivocal, or inconsistent with human outcomes.
Consequently, animal data may not normally be assumed to be useful for these purposes.
Non-animal models are generally required to pass formal scientific validation prior to regulatory
acceptance. In contrast, animal models are simply assumed to be predictive of human outcomes.
However, these 27 systematic reviews of the human utility of animal experiments demonstrate the
invalidity of such assumptions, even for animal models in use for long periods.
The consistent application of formal validation studies to all test models is clearly warranted, regardless of
their animal, non-animal, historical, contemporary or possible future status, with appropriate consideration
also given to animal welfare, ethical, legal, economic and any other appropriate factors. Likely benefits
would include greater selection of models truly predictive for human outcomes, increased safety of people
exposed to chemicals that have passed toxicity tests, increased efficiency during the development of
human pharmaceuticals and other therapeutic interventions, and decreased wastage of animal, personnel
and financial resources.

In addition, the poor human clinical and toxicological utility of most animal models for which data exists, in
combination with their generally substantial animal welfare and economic costs, justify considerably
greater rigor within the design of most animal studies, and a ban on the use of animal models lacking
scientific data clearly establishing their human predictivity or utility.
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